Acquisition of generic drug business

Hikma Pharmaceuticals
2015 - 2016

Our attorneys represented Hikma Pharmaceuticals in its US$2 billion acquisition of the Roxane Laboratories generic drug business from Boehringer Ingelheim. In describing the importance of the transaction, Said Darwazah, Chief Executive Officer of Hikma has commented: “This transaction has significant strategic value for us, transforming our position and scale in the US generics market. Roxane’s impressive portfolio, attractive pipeline and R&D expertise, focusing on higher value, niche and differentiated products, will create a platform for sustainable long-term growth.”

Email Disclaimer